¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"infectious hepatitis immunization"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® fulminant hepatitis ÇÑ±Û Àü°Ý°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º °£¿°ÀÇ ÇÑ ÇüÀ¸·Î ±Þ¼º È²»öÀ§ÃàÁõÀ̶ó°íµµ ºÎ¸¥´Ù. °£¼¼Æ÷ÀÇ ´ëºÎºÐÀÌ ±«»ç»óÅ·ΠµÇ¸ç È¯Àڴ º¸Åë »ç¸ÁÇÑ´Ù. È²´ÞÀÌ ³ªÅ¸³ª±â ÀüºÎÅÍ À̹̠Áõ»óÀº ÇöÀúÈ÷ ÁøÇàÇÏ¿© È²´ÞÀÇ ÃâÇöµµ ºü¸£°í, ±Þ¼º ¹ß¿­À» ¼ö¹ÝÇϸç Á¡¸·À̳ª ÇÇÇÏÃâÇ÷À» º¼ ¼ö ÀÖ´Ù. °£ÀÇ ¾ÐÅëÀ» ¼ö¹ÝÇϴ ¼öµµ ÀÖ´Ù. À§Ãà¿¡ ÀÇÇÏ¿© °£Àº ÀÚÁÖ ÀÛ¾ÆÁø´Ù. ÃÖÈÄ¿¡´Â ÀǽÄÀå¾Ö¸¦ ÃÊ·¡ÇÏ¿© Á¹À½ÀÌ ¿À°í È¥¹Ì»óÅ·ΠµÇ¸ç °£¼ºÈ¥¼ö·Î ÁøÇàÇÏ¿© »ç¸ÁÇϰԠµÈ´Ù. Áõ»óÀÌ ½ÃÀ۵Ǿî 2~3ÁÖ ³»¿¡ °£³úº´Áõ±îÁö ÁøÇàÇϴ °£±â´É »ó½ÇÀ» Àü°Ý¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸£¸ç, ÁøÇà ¼Óµµ°¡ ºü¸£Áö ¾Ê¾Æ¼­ 3°³¿ù¿¡ À̸£·¯ °£±â´É»ó½Ç¿¡ ºüÁö´Â °ÍÀº ¾Æ±Þ¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸¥´Ù. ¸ðµç °£¿° ¹ÙÀÌ·¯½º°¡ ¸ðµÎ ÀÏÀ¸Å°Áö´Â ¾Ê´Â´Ù. °£¿°A¹ÙÀÌ·¯½º¿Í °£¿°E¹ÙÀÌ·¯½º´Â º¸À¯ÀÚ »óųª ¸¸¼º °£¿°À» °ÅÀÇ ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. ±âŸ ´Ù¸¥ °¨¿° ¶Ç´Â ºñ°¨¿°¼º ¿øÀÎ, Æ¯È÷ ¾à¹°°ú µ¶¼Òµµ º»ÁúÀûÀ¸·Î µ¿ÀÏÇÑ ÁõÈĸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Áø´Ü°ú °¢ °£¿° ¹ÙÀÌ·¯½º¸¦ ±¸º°Çϴµ¥´Â Ç÷ûÇÐÀû °Ë»ç°¡ ÇʼöÀûÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infectious intensity
    °¨¿°³óµµ, °¨¿°°­µµ
  • infectious mononucleosis
    °¨¿°´ÜÇÙ±¸Áõ
  • infectious unit
    °¨¿°À¯¹ß´ÜÀ§
  • law of prophylaxis for infectious disease
    Àü¿°º´¿¹¹æ¹ý
  • rheumatismus infectious specificus
    ƯÀÌÀü¿°·ù¸ÓƼÁò
  • simple infectious glossitis
    ´Ü¼øÀü¿°Çô¿°, ´Ü¼øÀü¿°¼³¿°
  • anicteric hepatitis
    ¹«È²´Þ°£¿°
  • autoimmune hepatitis
    ÀÚ°¡¸é¿ª°£¿°
  • acute hepatitis
    ±Þ¼º°£¿°
  • alcoholic hepatitis
    ¾ËÄڿ𣿰
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
  • cholangiolitic hepatitis
    ¾µ°³¼¼°ü¿°¼º°£¿°, ´ã¼¼°ü¿°¼º°£¿°
  • cholestatic hepatitis
    ¾µ°³ÁóÁ¤Ã¼°£¿°, ´ãÁóÁ¤Ã¼°£¿°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic hepatitis
    ¸¸¼º°£¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infectious enterohepatitis
    Àü¿°Ã¢ÀÚ°£¿°, Àü¿°Àå°£¿°
  • simple infectious glossitis
    ´Ü¼øÀü¿°Çô¿°
  • infectious heredity
    Àü´ÞÀ¯Àü
  • infectious
    °¨¿°-
  • infectious intensity
    °¨¿°³óµµ, °¨¿°°­µµ
  • infectious mononucleosis
    Àü¿°´ÜÇÙ±¸Áõ
  • infectious unit
    °¨¿°À¯¹ß·®´ÜÀ§
  • law of prophylaxis for infectious disease
    Àü¿°º´¿¹¹æ¹ý
  • alcoholic hepatitis
    ¾ËÄڿ𣿰
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
  • anicteric hepatitis
    ¹«È²´Þ°£¿°
  • autoimmune hepatitis
    (¢¡chronic active hepatitis) ¸¸¼ºÈ°µ¿°£¿°
  • hepatitis B core antigen
    ºñÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    ºñÇü°£¿°Ç¥¸éÇ׿ø
  • cholangiolitic hepatitis
    (¢¡cholestatic hepatitis) ´ãÁóÁ¤Ã¼°£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Infectious Diseases Society of America
    ¹ÌÁÖ°¨¿°º´Çùȸ
  • acute infectious disease
    ±Þ¼º °¨¿°Áúȯ
  • acute infectious disease =AID
    ±Þ¼º Àü¿°º´(¡­îîæøÜ»).
  • acute infectious gastroenteritis =epidemic viral
    ±Þ¼ºÀü¿°¼ºÀ§Àå¿°(¡­îîæøêÖíóæú).
  • acute infectious gastroenteritis =epidermic viral g.
    ±Þ¼º Àü¿°¼º À§Àå¿°(¡­îîæøàõêÖ æú).
  • acute infectious hemorrhagic fever
    ±Þ¼º Àü¿°¼º ÃâÇ÷¿­(¡­îîæøàõõóúìæð).
  • acute infectious hemorrhagic fever
    ±Þ¼º°¨¿°¼ºÃâÇ÷¿­(õóúìæð)
  • acute infectious lymphocytosis
    ±Þ¼º Àü¿°¼º ¸²ÇÁ±¸ Áõ°¡Áõ.
  • glossitis, simple infectious
    īŸ¸£¼º ¼³¿°
  • infectious
    °¨¿°¼º(Êïæøàõ)ÀÇ.
  • infectious (-tive) DNA
    °¨¿°¼º DNA
  • infectious abortion
    °¨¿°À¯»ê.
  • infectious anemia
    °¨¿°¼º ºóÇ÷.
  • infectious arteritis
    °¨¿°¼º µ¿¸Æ¿°(¡­àõ ÔÑØææú)
  • infectious arthritis
    °¨¿°¼º °üÀý¿°(ÊïæøàõÎ¼ï½æú).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunization, prophylactic
    ¿¹¹æ¸é¿ª
  • oral immunization
    °æ±¸¸é¿ª(¹ý)(ÌèÏ¢Øóæ¹Ûö).
  • oral immunization
    °æ±¸¸é¿ª(¹ý)(Ë­Ë´ËÎËçËÑ).
  • passive immunization
    ¼öµ¿¸é¿ª(áôÔÑØóæ¹).
  • prophylactic immunization
    ¿¹¹æÁ¢Á¾
  • acute infectious disease
    ±Þ¼º °¨¿°Áúȯ
  • acute infectious disease =AID
    ±Þ¼º Àü¿°º´(¡­îîæøÜ»).
  • acute infectious gastroenteritis =epidemic viral
    ±Þ¼ºÀü¿°¼ºÀ§Àå¿°(¡­îîæøêÖíóæú).
  • acute infectious gastroenteritis =epidermic viral g.
    ±Þ¼º Àü¿°¼º À§Àå¿°(¡­îîæøàõêÖ æú).
  • acute infectious hemorrhagic fever
    ±Þ¼º°¨¿°¼ºÃâÇ÷¿­(õóúìæð)
  • acute infectious hemorrhagic fever
    ±Þ¼º Àü¿°¼º ÃâÇ÷¿­(¡­îîæøàõõóúìæð).
  • acute infectious lymphocytosis
    ±Þ¼º Àü¿°¼º ¸²ÇÁ±¸ Áõ°¡Áõ.
  • agent, infectious
    °¨¿°Ã¼, °¨¿°¿ø
  • avian infectious bronchitis virus
    Á¶·ù°¨¿°¼º±â°üÁö¿°¹ÙÀÌ·¯½º
  • avian infectious laryngotracheitis virus
    Á¶·ù°¨¿°¼ºÈĵαâ°üÁö¿°¹ÙÀÌ·¯½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IH idiopathic hirsutism; idiopathic hypercalciuria; immediate hypersensitivity; incompletely healed; in...
IHH idiopathic hypogonadotropic hypogonadism; idiopathic hypothalamic hypogonadism; infectious human hep...
ACIP acute canine idiopathic polyneuropathy; Advisory Committee on Immunization Practices [CDC]
DPI daily permissible intake; days post inoculation; dietary protein intake; diphtheria-pertussis immuni...
EPI echo planar imaging; electronic portal imaging; Emotion Profile Index; epilepsy; epinephrine; epithe...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CIAV Chicken infectious anemia virus
EIA Equine Infectious Anemia
EIAV Equine Infectious Anemia Virus
FIP Feline Infectious Peritonitis
FIPV Feline Infectious Peritonitis Virus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute hepatitis
    ±Þ¼º °£¿°
    ÀÌ º´¸íÀº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º¡¤½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀ̰í, °£µ¶¡¤È­Çоàǰ¡¤ÀǾàǰ µîÀ¸·Î »ý±â´Â Áßµ¶¼º °£¿°µµ ºñ±³Àû ¸¹´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༺ °£¿°
  • cholestatic hepatitis
    ´ãÁó ¿ïü¼º °£¿°, ´ãÁó Á¤Ã¼¼º °£¿°
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • chronic hepatitis B
    ¸¸¼º BÇü °£¿°
  • epidemic hepatitis
    À¯Ç༺ °£¿°
  • hepatitis
    °£¿°
    °£ÀÇ ¿°Áõ¼º Áúȯ. °£Àå¿°À̶ó°íµµ ÇÑ´Ù. °£ ÁúȯÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â °ÍÀ¸·Î¼­, Å©°Ô ±Þ¼º °£¿°°ú ¸¸¼º °£¿°À¸·Î ³ª´«´Ù. ¡¼±Þ¼º °£¿°¡½ ÀÌ º´¸íÀº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º, ½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀ̰í, °£µ¶, È­ÇÐ ¾àǰ, ÀǾàǰ µîÀ¸·Î »ý±â´Â Áßµ¶¼º °£¿°µµ ºñ±³Àû ¸¹´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༺ °£¿°
  • hepatitis A
    AÇü °£¿°
    AÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© ¹ß»ýÇÏ´Â Àü¼¼°èÀûÀ¸·Î ºÐÆ÷µÈ ÀÚ±â ÇÑÁ¤¼º ¹ÙÀÌ·¯½º¼º ÁúȯÀ¸·Î¼­, À§»ý »óŰ¡ ³ª»Ú°í °æÁ¦ ¼öÁØÀÌ ³·Àº Áö¿ª¿¡ ´õ¿í ¸¹ÀÌ ¹ß»ýÇÏ¸ç ºñ°æ±¸Àû °¨¿°µµ °¡´ÉÇϱâ´Â Çϳª °ÅÀÇ ÀüÀûÀ¸·Î ´ëº¯ °æ±¸ °æ·Î¸¦ ÅëÇÏ¿© ÀüÆÄµÇ°í, º¸±ÕÀÚ »óÅ´ »ý±âÁö ¾Ê´Â´Ù. Àẹ ±â°£Àº 15-20ÀϷμ­ Æò±Õ 30ÀÏÀÌ´Ù. ´ë´Ù¼ö ȯÀÚ´Â ÀÓ»ó Áõ¼¼°¡ ¶Ñ·ÇÇÏÁö ¾Ê°Å³ª °æÇÑ °¨±â Áõ»óÀ» ³ªÅ¸³»¸ç Ȳ´ÞÀº ÀÖ´õ¶óµµ ¸Å¿ì °æ¹ÌÇÏ´Ù. ±¤¹üÀ§ÇÑ °£ ±«»ç°¡ ÀϾ ¼ö ÀÖÀ¸³ª BÇü °£¿°¿¡¼­ º¸´Ù´Â ÈξÀ Àû°Ô ³ªÅ¸³­´Ù.
  • hepatitis B
    BÇü °£¿°
    BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ °£ÀÇ ¿°Áõ¼º ÁúȯÀ¸·Î¼­ Àü¼¼°èÀûÀ¸·Î À¯ÇàÇϸç À¯ÇàÀÌ °¡Àå ³ôÀº Áö¿ªÀº Áß°î°ú µ¿³²¾Æ, »çÇ϶ó ÁÖº¯ ¾ÆÇÁ¸®Ä«, ÅÂÆò¾ç±ºµµÀÇ ´ëºÎºÐ ¹× ¾Æ¸¶Á¸ À¯¿ª µîÀÌ´Ù.
  • hepatitis B virus
    BÇü °£¿° ¹ÙÀÌ·¯½º
    1. BÇü °¨¿° ȯÀÚ¿¡¼­ ¸ðµç ü¾× ³»·Î ¹æÃâµÇ´Â ¹ÙÀÌ·¯½º. 2. »ç¶÷ÀÇ °£¿¡ »ì¸ç, Ç÷û °£¿° µîÀ» ÀÏÀ¸Å°´Â ¹ÙÀÌ·¯½º. HB ¹ÙÀÌ·¯½º¶ó°íµµ ÇÑ´Ù. HBs Ç׿ø, HBc Ç׿ø, HBe Ç׿ø µî ¼¼ Á¾·ùÀÇ Ç׿ø ´Ü¹éÁúÀ» Áö´Ñ ¹ÙÀÌ·¯½ºÀÌ´Ù. ÀÌ °¡¿îµ¥ HBs Ç׿ø¿¡´Â º¹¼öÀÇ Ç׿ø °áÁ¤±â°¡ ÀÖ¾î, ±× ¦¸ÂÃã¿¡ µû¶ó BÇü °£¿° ¹ÙÀÌ·¯½º´Â adr, adw, ayr, aywÀÇ 4°¡Áö ¾ÆÇüÀ¸·Î ³ª´©¾îÁ® ÀÖ´Ù. 1965³â ¹Ì±¹ÀÇ S. ºí·³¹ö±×°¡ ¿À½ºÆ®·¹Àϸ®¾Æ ¿øÁÖ¹ÎÀÇ Ç÷û¿¡¼­ ¹ß°ßÇÏ¿© ´çÃÊ¿¡´Â Ç׿ø¼ºÀÌ ÀÖ´Â ¹°ÁúÀ̶ó°í º¸°í, HB Ç׿ø ¶Ç´Â ¿À½ºÆ®·¹Àϸ®¾Æ Ç׿øÀ̶ó°í ºÒ·¶´Ù. ±× ÈÄ DNA
  • lupoid hepatitis
    ·çÇÁ½º¾ç °£¿°, À¯³¶Ã¢ °£¿°
    ¼Ò±¸Áø»ó º´º¯À» Ư¡À¸·Î ÇÏ´Â À¯À°Á¾ÁõÀÇ °£¿°.
  • neonatal hepatitis
    ½Å»ý¾Æ °£¿°
  • serum hepatitis
    Ç÷û °£¿°
    ¹ÙÀÌ·¯½º¼º °£¿° Áß BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© °£ÀÌ Ä§ÇØµÇ´Â º´. Áõ¼¼´Â À¯Ç༺ °£¿°°ú º»ÁúÀûÀ¸·Î´Â ´Ù¸¦ ¹Ù°¡ ¾ø´Ù. ´Ù¼Ò ¿Ï¸¸ÇÏ°Ô ½ÃÀÛµÇÁö¸¸ °æ°ú°¡ ±æ°í, ¸¸¼ºÈ­ÀÇ °æÇâµµ °­ÇÏ´Ù. Àẹ±â´Â 60¡­90ÀÏÀε¥, ¼öÇ÷ ÈÄ 20ÀÏ Á¤µµ·Î ³ªÅ¸³ª´Â ¼öµµ ÀÖ´Ù. °¨¿° °æ·Î´Â Ç÷¾× ¹× Ç÷¾×Á¦Á¦
  • viral hepatitis
    ¹ÙÀÌ·¯½º °£¿°, ¹ÙÀÌ·¯½º¼º °£¿°
    ÃÖ¼Ò 5Á¾ÀÇ ¼­·Î ´Ù¸¥ ¹ÙÀÌ·¯½º°¡ ¿øÀÎÀÌ µÇ¸ç ÀÌµé ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î ÀÎÇÑ °£¿°.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
german measles immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (German measles). The MMR vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or MMR vaccination prior to entrance. Most children should receive MMR vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the MMR vaccine. Pregnant women should wait until after delivery before being immunised with MMR. People with HIV or AIDS should normally receive MMR vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
passive immunization The production of passive immunity.
(05 Mar 2000)
measles immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
chickenpox immunization This vaccine prevents the common disease known as chickenpox (varicella zoster). While chickenpox is often considered a trivial illness, it can cause significant lost time on the job and in school and have serious complications including ear infections, pneumonia, and infection of the rash with bacteria, inflammation of the brain (encephalitis) leading to difficulty with balance and coordination (cerebellar ataxia), damaged nerves (palsies), and Reye's syndrome, a potentially fatal complication. The vaccination requires only one shot given at about a year of age. If an older person has not had chickenpox, the shot may be given at any time. There have been few significant reactions to the chickenpox vaccine. All children, except those with a compromised immune system, should have the vaccination.
(12 Dec 1998)
rubella immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
mumps immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
pneumococcal pneumonia immunization This vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children.
(12 Dec 1998)
polio immunization <virology> The vaccines available for vaccination against polio are opv (oral polio vaccine) and ipv (inactivated polio vaccine).
Opv is still the preferred vaccine for most children. As its name suggests, it is given by mouth.
Ipv, or inactivated polio vaccine is given as a shot in the arm or leg. Infants and children should be given four doses of opv. The doses are given at 2 months, 4 months, 6-18 months and 4-6 years of age.
Persons allergic to eggs or the drugs neomycin or streptomycin should receive opv, not the injectable ipv. Conversely, ipv should be given if the vaccine recipient is on long-term steroid (cortisone) therapy, has cancer, or is on chemotherapy or if a household member has aids or there is an unimmunised adult in the house.
(21 Jun 1999)
haemophilus influenzae type b immunization See HIB immunization,
(12 Dec 1998)
hib immunization This vaccine is to prevent disease caused by the haemophilus influenzae type b (hib) bacteria. The h. Influenzae (h. Flu) bacteria can cause a range of serious diseases including meningitis with potential brain damage and epiglottitis with airway obstruction poisoning. The hib vaccine is usually given at 2, 4 and 6 months of age. A final booster is given at 12-15 months of age. Hib vaccine rarely causes severe reactions.
(12 Dec 1998)
dpt immunization DPT immunization protects from diphtheria, pertussis (whooping cough), and tetanus and is given in a series of 5 shots at 2, 4, 6, 18 months of age and 4-6 years of age. Thanks to vaccination programs, these diseases have become less common. However, there are still unvaccinated individuals capable of carrying and passing diphtheria and pertussis to others who are not vaccinated. Tetanus bacteria are prevalent in natural surroundings, such as contaminated soil. See also DTaP immunization.
(12 Dec 1998)
dtap immunization Like DPT, DTaP protects from diphtheria, pertussis (whooping cough) and tetanus. DTaP is the same as DTP, except that it contains only acellular pertussis vaccine which is thought to cause fewer of the minor reactions associated with immunization and is also probably less likely to cause the more severe reactions occasionally seen following pertussis vaccination. DTaP is currently recommended only for the shots given at 18 months and 4-6 years of age.
(12 Dec 1998)
dt immunization DT (diphtheria and tetanus) vaccine does not protect from pertussis and is usually reserved for individuals who have had a significant adverse reaction to a DPT shot or who have a personal or family history of a seizure disorder or brain disease.
(12 Dec 1998)
immunization <immunology> A process that increases an organisms reaction to antigen and therefore improves its ability to resist or overcome infection.
<technique> A technique used to induce immune resistance to a specific disease in humans (or other mammals) by exposing the individual to an antigen in order to raise antibodies to that antigen.
(13 Oct 1997)
immunization, anthrax A series of six shots over six months and booster shots annually, the anthrax vaccine now in use in the usa was first developed in the 1950s and approved by the food and drug administration for general use in 1970. It is produced by the michigan biologic products institute of michigan's department of health and is given routinely to veterinarians and others working with livestock. In december, 1997 it was announced that all us military would receive the vaccine, as do the military in the uk and russia, the reason being concern that anthrax might be used in biologic warfare.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á